Last updated: April 26, 2026
Who supplies anagrelide hydrochloride (API)
Anagrelide hydrochloride is supplied through a mix of branded manufacturers, authorized generics, and contract manufacturing organizations (CMOs) that produce the active pharmaceutical ingredient (API) under global regulatory frameworks. Market access is typically via DMFs (US), CEPs (EU), and local registrations tied to strength, salt form, polymorph, and impurity profile.
API supplier channels to target in procurement
- Originator/brand manufacturers and their supply chains (often via authorized API distributors)
- DMF holders for anagrelide HCl (API-level qualification path for generics)
- CMOs with anagrelide HCl capability (scale-up and batch release under ICH Q-series)
- Chemical sourcing via salt conversion (where anagrelide base is converted to hydrochloride under controlled impurity specs)
What procurement screens typically require for anagrelide HCl
- Strength coverage (commonly tied to finished-dose products, e.g., 0.5 mg capsule/tablet manufacturing)
- Salt form confirmation: anagrelide hydrochloride (not free base)
- Impurity limits aligned to drug product specs and ICH Q3A/Q3B expectations
- Analytical package: CoA, HPLC/GC methods, residual solvents, metal catalysts, water content
- Regulatory status: DMF (US), CEP (EU), GMP certification for API manufacturing sites
Which finished-dose manufacturers supply anagrelide hydrochloride tablets/capsules
Finished-dose supply tends to be concentrated in established generic brands and regional distributors. Drug product availability depends on local regulatory approvals, packaging sizes, and substitution rules.
Procurement mapping approach (drug product)
- Source through authorized wholesalers for market-ready product
- Confirm NDC/MA number, strength (commonly 0.5 mg), dosage form (tablet/capsule), and excipient system
- Require batch-specific CoA and sterility/bioburden where applicable (for non-sterile oral solids, primary focus is assay and impurities)
- Validate labeling: strength and dosing instructions consistent with local monographs
What suppliers sell: API vs intermediates vs salts
Anagrelide hydrochloride supply frequently breaks into three procurement categories:
| Supply item |
Typical supplier type |
What buyers verify |
| Anagrelide hydrochloride API |
DMF-holding API manufacturers, specialty chemical pharma suppliers |
DMF/CEP status, impurity profile, polymorph/salt form, GMP CoA |
| Anagrelide base (free base) |
Intermediate manufacturers / API upstream suppliers |
Conversion feasibility to HCl, impurity carryover controls |
| Anagrelide hydrochloride salt conversion |
Chemical processors |
Salt specification control, residual solvents, chloride assay, solid-state confirmation |
How to identify credible anagrelide HCl suppliers fast
Use supplier qualification gates that prevent rework and regulatory delays:
Qualification gates (minimum set)
- Regulatory file alignment: confirm a pathway to your application (DMF letter, CEP reference, or audit-ready GMP evidence)
- GMP status: current manufacturing authorization for API site and batch release testing
- Quality dossier: CoA frequency, impurity panel, stability data availability
- Supply reliability: multi-batch continuity, lead time, and change-control history
Contracting clauses to lock early
- Change control notification windows for route/process impurities
- Right to audit and documentation access (Master Batch Records, batch data, method traceability)
- Specifications lock for key impurities and residual solvents
- Handling of investigations, out-of-spec results, and deviations
Supplier due diligence checklist for anagrelide hydrochloride
Use this screening sequence for API and drug product procurement:
- Documentation: DMF/CEP number match to proposed site and grade
- Quality: impurity control strategy and method validation status
- Consistency: historical CoA trend on assay and top impurities
- GMP: inspection history and corrective actions
- Supply: forecast adherence, MOQ, packaging (for API), and logistics lane control
- Regulatory support: ability to provide letter support (where applicable) and common technical transfers
Key Takeaways
- Anagrelide hydrochloride supply is sourced primarily through DMF/CEP-linked API manufacturers and regional finished-dose generic manufacturers.
- Fast qualification depends on regulatory-file alignment (DMF/CEP), impurity control evidence, and GMP batch release traceability.
- Procurement should separate API vs salt-conversion vs drug product, then apply batch-specific CoA and solid-form confirmation for anagrelide HCl.
FAQs
-
Is anagrelide hydrochloride typically supplied as an API DMF product or through wholesalers?
It is usually procured as an API from DMF-holding manufacturers for regulatory submission use, while finished-dose product is commonly sourced through wholesalers.
-
What is the key quality risk when buying anagrelide hydrochloride?
Salt form correctness and impurity profile alignment with the target drug product specifications.
-
Do suppliers provide stability data for anagrelide HCl API?
Reputable API suppliers provide stability support and batch-specific analytical summaries as part of technical packages.
-
Is it acceptable to source anagrelide base and convert to hydrochloride in-house?
It can be done, but procurement must validate conversion controls, residual impurities, and solid-state confirmation for hydrochloride consistency.
-
What should buyers require from the supplier before release-to-manufacture?
Batch-specific CoA, analytical methods or method summaries, GMP documentation for the manufacturing site, and an agreed specification sheet including key impurities and residual solvents.
References
- U.S. Food and Drug Administration. “Drug Master Files (DMFs).” FDA. https://www.fda.gov/drugs/dmfs-drug-master-files.
- European Medicines Agency. “Certification of Suitability (CEP) to the Ph. Eur.” EMA. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/cep-certification-suitability-ph-eur.
- International Council for Harmonisation. “ICH Q3A(R2): Impurities in New Drug Substances.” ICH. https://www.ich.org/.
- International Council for Harmonisation. “ICH Q3B(R2): Impurities in New Drug Products.” ICH. https://www.ich.org/.
- International Council for Harmonisation. “ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients.” ICH. https://www.ich.org/.
